|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas.
|
8649842 |
1996 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
DNA analysis of tumour tissue showed loss of heterozygosity for the cylindromatosis CYLD1 locus.
|
9783709 |
1998 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Previously, the HC gene (CYLD1) was linked to chromosome 16q12-13, and tumors showed loss of heterozygosity (LOH), suggesting that CYLD1 is a tumor suppressor gene.
|
10480375 |
1999 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In affected families, mutations have been demonstrated in the CYLD gene located on chromosome 16q12-13 and reveal the characteristic attributes of a tumor suppressor.
|
12190880 |
2002 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We conclude that somatic mutation of the CYLD1 gene outside the skin can have a role in the oncogenesis of tumors with cylindromatous features.
|
11756779 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Increases in copy numbers of the LAMC2, TGFB2, and AKT3 genes (located on 1q) and decreases in copy numbers of FGR/SRC2 and CYLD (located on 1p and 16q, respectively) were observed in more than 30% of tumors, including small, well-differentiated carcinomas.
|
15133472 |
2004 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD in ubiquitin signaling and tumor pathogenesis.
|
16713556 |
2006 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumor suppressor gene related to cylindroma and is negative regulator of NF-kappaB.
|
16627981 |
2006 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Thus, functional relevant loss of CYLD expression may contribute to tumor development and progression, and may provide a new target for therapeutic strategies.
|
16774947 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, we delineate how CYLD interferes with activation of the proto-oncogene Bcl(3) and with cyclin D1 expression to limit tumorigenesis, and chart how tumor growth-promoting agents or UV light and inflammatory mediators can activate CYLD.
|
18008375 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
More specifically, our results highlight STAT6 as a potential transcriptional target and identified RGMA, CHD2 and CYLD as candidate tumor suppressors in cHL.
|
17606441 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The loss of CYLD gene of tumor suppressor gene, 16q12-q13, was only on locus of common involvement in 3 cell lines.
|
18799932 |
2008 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Pathogenic truncations of the CYLD C terminus, associated with the hypertrophic skin tumor cylindromatosis, disrupt the USP domain, accounting for loss of CYLD catalytic activity.
|
18313383 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
|
18193168 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Of these potential substrates, serine 418 of the tumor suppressor CYLD was identified as a likely site of IKKepsilon phosphorylation.
|
19481526 |
2009 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
|
19917957 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Recent studies indicate that CYLD is a tumour-suppressor gene.
|
19076795 |
2009 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Rescue of CYLD expression in melanoma cells reduced proliferation and invasion in vitro and tumor growth and metastasis in vivo.
|
19124656 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our recent work has shown that breast cancer cell adhesion to vascular endothelial cells activates endothelial MMP-2, promoting tumor cell transendothelial migration (TEM(E)).
|
20571065 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Together, our results argue that loss of CYLD instigates tumor growth in human cylindromatosis through a mechanism in which hyperubiquitination of polymerized Dvl drives enhancement of Wnt responses.
|
20227366 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The deubiquitinating enzyme CYLD is a negative regulator of NF-kappaB and known to function as a tumor suppressor.
|
20607853 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD(C/S) tumors are also characterized by their elevated proliferation rate and decreased apoptosis.
|
20838385 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumour-suppressor gene that is mutated in a benign skin tumour syndrome called cylindromatosis.
|
19893491 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Since loss of CYLD expression can be observed in different types of human cancer, it is now well established that CYLD acts as a tumor suppressor gene.
|
21345146 |
2011 |